Joincare: In the third quarter, the net profit attributable to the parent company was 306 million yuan, a year-on-year decrease of 8.61%Zhitong·Oct 24, 2025 at 12:58 PM600380+0.58%
Joincare: Net profit in the first half of the year was 785 million yuan, a year-on-year increase of 1.1%Zhitong·Aug 22, 2025 at 02:26 PM600380+0.58%
Joincare: The company has currently laid out more than 20 types of Class 1 innovative drugsZhitong·Aug 1, 2025 at 08:39 AM600380+0.58%
The innovative drug sector remains active, WBDE and MEDISAN saw their stocks locked in the afternoonZhitong·Jul 16, 2025 at 05:50 AM002900-3.11%000513+0.44%
BRII-B signed an intellectual property licensing and technology transfer agreement with Joincare GroupZhitong·Jul 4, 2025 at 12:35 AM600380+0.58%02137+0.95%
Joincare: YJH-012 injection approved to conduct clinical trialsZhitong·Jun 24, 2025 at 07:44 AM000513+0.44%01513+1.63%
Joincare: JKN2301 dry mixed suspension has received clinical trial approvalZhitong·Jun 19, 2025 at 09:13 AM600380+0.58%
KaiYuan Securities: Pipeline layout enters harvest period, 2025 marks the beginning of the new era for domestic influenza drugsZhitong·Jun 16, 2025 at 03:55 AM02096-2.85%600566+0.44%
The concept of innovative drugs is booming, and many companies have recently received collective research from institutionsZhitong·May 31, 2025 at 01:23 AM600380+0.58%
Joincare's Dutch subsidiary has obtained a production licenseZhitong·May 29, 2025 at 08:39 AM600380+0.58%
Joincare: Lijun microsphere injectable aripiprazole microspheres approved for market launchZhitong·May 9, 2025 at 09:51 AM600380+0.58%
Joincare released its first-quarter performance, with a net profit attributable to the parent company of 436 million yuan, a year-on-year decrease of 0.91%Zhitong·Apr 24, 2025 at 03:18 PM600380+0.58%
